

MEDIA RELEASE

For immediate release

ACROMEC secures S\$8.7 million contract from new customer in pharmaceutical industry

- Added new customer
- Strengthened our position in pharmaceutical industry
- Contract win brings cumulative order book to approximately \$\$42 million

SINGAPORE, 7 February 2017 - ACROMEC Limited ("ACROMEC", or the "Company" and together with its subsidiary, the "Group"), an established specialist engineering service provider in the field of controlled environments serving mainly the healthcare, biomedical, research and academia sectors, has today secured a contract worth \$\$8.7 million (the "Contract"). The Contract is for the fitting-out of production facilities in an extension project to an existing pharmaceutical plant for an esteemed customer in the pharmaceutical industry. The Contract is expected to be completed by the third quarter of the current financial year ending 30 September 2017 ("FY2017").

Acromec has been engaged to fit-out production facilities that meet good manufacturing practices with cleanliness classification of Grades 3 and 4. These facilities which spread over three levels and connect to the main building facilities, will provide an additional 1,680 square metres of space.

Our customer is part of a leading Group in the life science industries that is one of the world's most-trusted suppliers that harness science and technology to create products that make people's and animals' lives healthier thereby improving the overall quality of life and well-being.

Mr Lim Say Chin, Executive Chairman and Managing Director of ACROMEC, said: "We are honoured to be given an opportunity to support the growth and expansion plans of our new customer, and we are grateful to them for their trust in us. This award is a continued testament of Acromec's established track record which we have successfully built over the years. We have also strengthened our position in the growing pharmaceutical industry with this solid win."

Acromec has a healthy order book which currently stands at approximately S\$42 million as at date of this announcement.

The Contract is expected to contribute positively to the earnings per share and net tangible assets per share of the Group for FY2017.

None of the Directors of the Company has any interest, direct or indirect, in the Contract, other than through their respective shareholdings in the Company. To the best of the Directors'



knowledge, none of the controlling shareholders of the Company has any interests, direct or indirect, in the Contract, other than through their respective shareholdings in the Company.



About ACROMEC Limited (SGX Stock Code: 1CH1)

ACROMEC is an established specialist engineering services provider with 20 years of experience in the field of controlled environments. The Group has over the years acquired expertise in the design and construction of facilities requiring controlled environments such as laboratories, medical and sterile facilities and cleanrooms.

ACROMEC's business is divided into two main business segments: (i) Engineering, procurement and construction services, specialising in architectural, and mechanical, electrical and process works within controlled environments; and (ii) Maintenance and repair services for facilities and equipment of controlled environments and their supporting infrastructure.

The Group mainly serves the healthcare, biomedical, research and academia, and electronics sectors. ACROMEC counts amongst its customers, hospitals and medical centres, government agencies, research and development companies or agencies, research and development units of multinational corporations, tertiary educational institutions, pharmaceutical companies, semiconductor manufacturing companies, and multinational engineering companies. For more information, please visit www.acromec.com.

Media and Analysts Contact:

Acromec Limited
Mr Jerry Tan
Chief Financial Officer

Tel: +65 6415 0574

Email: jerry.tan@acromec.com

Waterbrooks Consultant Pte Ltd

Mr Ma Kin Hoong Mobile: +93840073

Email: ma@waterbrooks .com.sg

This media release has been prepared by ACROMEC and its contents have been reviewed by the Company's Sponsor, SAC Capital Private Limited (the "Sponsor"), for compliance with the relevant rules of the Singapore Exchange Securities Trading Limited (the "SGX-ST"). The Sponsor has not independently verified the contents of this media release.

This media release has not been examined or approved by the SGX-ST. The Sponsor and the SGX-ST assume no responsibility for the contents of this media release, including the correctness of any of the statements or opinions made or reports contained in this media release.

The contact person for the Sponsor is Mr Ong Hwee Li (Telephone: +65 6532 3829) at 1 Robinson Road #21-02 AIA Tower, Singapore 048542.